Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit PR Newswire - Thu Mar 26, 10:04PM CDT

NEW YORK , March 26, 2026 /PRNewswire/ --

CORT : 38.53 (-4.79%)
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss PR Newswire - Thu Mar 26, 3:42PM CDT

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline

CORT : 38.53 (-4.79%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines - CORT PR Newswire - Thu Mar 26, 9:00AM CDT

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such...

CORT : 38.53 (-4.79%)
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer Business Wire - Wed Mar 25, 11:43AM CDT

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic...

CORT : 38.53 (-4.79%)
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Corcept Therapeutics Incorporated(CORT) Shareholders PR Newswire - Wed Mar 25, 8:00AM CDT

NEW YORK , March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of...

CORT : 38.53 (-4.79%)
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire - Tue Mar 24, 2:35PM CDT

BENSALEM, Pa. , March 24, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

CORT : 38.53 (-4.79%)
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss PR Newswire - Tue Mar 24, 11:30AM CDT

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline

CORT : 38.53 (-4.79%)
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit -- The Gross Law Firm PR Newswire - Tue Mar 24, 8:00AM CDT

NEW YORK , March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).

CORT : 38.53 (-4.79%)
Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately PR Newswire - Tue Mar 24, 7:49AM CDT

Lead Plaintiff Deadline is April 21, 2026

CORT : 38.53 (-4.79%)
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire - Mon Mar 23, 3:37PM CDT

LOS ANGELES , March 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:...

CORT : 38.53 (-4.79%)

Barchart Exclusives

The General Mills Dividend Yields 6.53%. Is That Enough to Make Up for an Oil Price Shock? Barchart - Thu Mar 26, 6:30PM CDT
General Mills’ high 6.53% dividend yield may look enticing, but it comes amid falling earnings, rising oil-driven cost pressures, and growing macro risks that could limit upside. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.